BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Business Intelligence

  Business Intellilgence

Aging, AI, and the Uneven Road to Longevity Medicine

by BiopharmaTrend   •   Dec. 11, 2025

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

Echoing notes from ARDD2025, we briefly overview geroscience, its fusion with AI, what companies pursue in this field and limitations on the way of longevity medicine.

А couple of weeks ago, our co-founder Andrii Buvailo, PhD outlined three main conclusions about the modern aging research landscape, drawing on discussions from ARDD2025 in Copenhagen, where he was present. Among other ideas, he makes a point that the recent conversion of aging research from theoretical into practical realm is heavily driven by AI, which is enabling better biological modeling, sharper insight into aging, and new ideas for confronting humanity’s core limitation.

There are other speakers highlighting the promises of AI for solving aging. Anthropic CEO Dario Amodei said at 2025 WEF that if AI dramatically accelerates biological research, doubling the human lifespan by around 2030 isn’t unrealistic because it could compress “100 years of progress” into 5–10 years. Such claims are controversial, but they reflect a real trend: AI is impacting both basic geroscience and emerging longevity medicine. Before delving deeper into the intersection of AI and longevity, let’s overview the history of this field before machines came.


In this article: Nothing Lasts Forever — Aging Hallmarks & AI — Seeking Philosopher’s Stone — To Practical Longevity


Nothing Lasts Forever

Aging is the gradual, time-dependent decline in the physiological functions required for survival and reproduction. Unlike age-related diseases (such as cancer or heart disease), the defining features of aging are shared by all individuals within a species.

As an integral part of life, aging has caused a multitude of philosophical disputes throughout history, tracing back to 350 BCE when Aristotle first tried to explain senescence, viewing it as a ‘natural illness’. However, conventional aging research started much later, in the 20th century.


Timeline of aging research. Adapted from “From discoveries in ageing research to therapeutics for healthy ageing”

Caloric restriction (CR) was an early breakthrough in aging research: in 1935, C. McCay showed that reducing calories in rodents increased lifespan. This effect was later reproduced across multiple species, including primates, providing early evidence that aging is biologically “plastic.” CR not only extends maximum lifespan but also delays or suppresses age-associated diseases, helping establish the idea that longer life can reflect slowed aging and improved healthspan—both total healthy years and the proportion of life spent disease-free.

In the mid-1900s, researchers debated whether aging “causes” chronic disease; although aging is the major risk factor, proving direct causality is difficult because many normal aging changes interact to drive dysfunction. These ideas, plus growing overlap between aging mechanisms and disease biology, helped form geroscience, distinct from broader gerontology.

Meanwhile, genetic approaches strengthened the field: Medawar’s 1952 evolution-inspired aging theory spurred fly selection experiments showing heritable lifespan differences, and a landmark 1988 C. elegans study revealed that single-gene mutations like age-1 can extend lifespan by ~40–60%. Since then, hundreds of lifespan-modulating genes have been identified, shifting the focus from describing aging traits to mapping shared pathways and homeostatic processes (including dietary restriction responses) that shape aging. Process-based paradigm underpinned the concept of aging hallmarks, firstly presented in 2013.


Aging Hallmarks & AI

Hallmarks of aging are defined as core biological processes that:

  1. manifest with age
  2. can accelerate aging when experimentally worsened
  3. can be slowed, halted, or partially reversed by interventions that target them

They’re not independent—changing one often affects others. The milestone 2013 work described which were later .

To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.

Gain full access to all of our deep dives and content archives.

 Upgrade to Pro 

Already a member? Sign in here.
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.